NCT04210206 is a NA clinical trial of PHE-diet in Phenylketonurias, sponsored by Klaus Parhofer.

Who is sponsoring NCT04210206?

NCT04210206 is sponsored by Klaus Parhofer.

What drugs are being tested in NCT04210206?

Interventions in NCT04210206: PHE-diet.

What condition does NCT04210206 study?

NCT04210206 studies Phenylketonurias.

Is NCT04210206 still recruiting?

NCT04210206 is currently terminated. Last updated 14 December 2023.

Last reviewed 2023-12-14 · How we verify

NCT04210206

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Short-term Effects of Good Metabolic Control on Cognitive Function, Wellbeing, and Metabolic Parameters in Adult Patients With Phenylketonuria

Terminated NA Last updated 14 December 2023

What this trial tests

NA trial testing PHE-diet in Phenylketonurias in 13 participants. Terminated before completion.

Timeline

1 December 2019

Primary endpoint
31 August 2023

31 August 2023

Quick facts

Lead sponsor	Klaus Parhofer
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	13
Start date	1 December 2019
Primary completion	31 August 2023
Estimated completion	31 August 2023
Sites	1 location across Germany

Drugs / interventions tested

PHE-diet

Conditions studied

Phenylketonurias — all drugs for Phenylketonurias →

Sponsor

Klaus Parhofer

Who can join

Adults 18 to 59, any sex, with Phenylketonurias. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this study is to evaluate if in adult patients with phenylketonuria (PKU) without strict metabolic control during the last 12 months, strict metabolic control for 8 weeks results in an improvement of cognitive function.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Phenylketonurias

Currently open trials in the same condition.

NCT06332807 — AAV Gene Therapy Clinical Study in Adult Classic PKU (PHEdom) · Phase 1, PHASE2 · recruiting
NCT06560736 — Development of Novel Psychological Assessment Tools and Anxiety Intervention for Phenylketonuria · NA · recruiting
NCT06718842 — Walking Program in Fatty Liver Children With Phenylketonuria · NA · recruiting
NCT06687733 — Safety and Efficacy Study of NGGT002 in cPKU Adult Subjects · Phase 1, PHASE2 · recruiting
NCT06061614 — Safety and Efficacy Study of NGGT002 in PKU Adult Subjects · EARLY_PHASE1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04210206 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Klaus Parhofer
Last refreshed: 14 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04210206.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing